TNSN08150A1 - Antagonistes du recepteur d'histamine h3 - Google Patents
Antagonistes du recepteur d'histamine h3Info
- Publication number
- TNSN08150A1 TNSN08150A1 TNP2008000150A TNSN08150A TNSN08150A1 TN SN08150 A1 TNSN08150 A1 TN SN08150A1 TN P2008000150 A TNP2008000150 A TN P2008000150A TN SN08150 A TNSN08150 A TN SN08150A TN SN08150 A1 TNSN08150 A1 TN SN08150A1
- Authority
- TN
- Tunisia
- Prior art keywords
- compound
- formula
- disorders
- congestion
- disorder
- Prior art date
Links
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 title 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 206010020751 Hypersensitivity Diseases 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000007815 allergy Effects 0.000 abstract 2
- 208000027744 congestion Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 102000004384 Histamine H3 receptors Human genes 0.000 abstract 1
- 108090000981 Histamine H3 receptors Proteins 0.000 abstract 1
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 206010028735 Nasal congestion Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000012886 Vertigo Diseases 0.000 abstract 1
- 230000009858 acid secretion Effects 0.000 abstract 1
- 230000008369 airway response Effects 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000035873 hypermotility Effects 0.000 abstract 1
- 230000036543 hypotension Effects 0.000 abstract 1
- 201000003152 motion sickness Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 231100000889 vertigo Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
L'invention concerne un composé de formule I telle que définie ici, Ou un de ses sels pharmaceutiquement acceptables ; une composition pharmaceutique contenant un composé de formule I, un procédé pour la préparation d'un composé de formule I, une méthode de traitement d'un trouble ou d'une affection qui peut être traité en antagonisant les récepteurs d' histamine H3, méthode comprenant l'administration à un mammifère ayant besoin d'un tel traitement d'un composé de formule l répondant à la description précitée, et une méthode de traitement d'un trouble ou d'une affection choisi dans le groupe consistant en la dépression, des troubles de l' humeur, la schizophrénie, des troubles de l'anxiété, la maladie d'Alzheimer, le trouble d'hyperactivité avec déficit d'attention (ADHD), des troubles psychotiques, des troubles cognitifs, des troubles du sommeil, l' obési té, les vertiges, l'épilepsie, le mal des transports, des maladies respiratoires, une allergie, des réponses des voies aériennes induites par une allergie, la rhinite allergique, la congestion nasale, la congestion allergique, la congestion, l' hypotension, une maladie cardio-vasculaire, des maladies du tractus GI, l'hypermotilité, l'hypomotilité et la sécrétion acide du tractus gastro-intestinal, méthode comprenant l'administration à un mammifère ayant besoin d'un tel traitement d'un composé de formule l répondant à la description précitée.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73099605P | 2005-10-27 | 2005-10-27 | |
| PCT/IB2006/002977 WO2007049123A1 (fr) | 2005-10-27 | 2006-10-16 | Antagonistes des récepteurs de l'histamine h3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN08150A1 true TNSN08150A1 (fr) | 2009-10-30 |
Family
ID=37776539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2008000150A TNSN08150A1 (fr) | 2005-10-27 | 2008-04-02 | Antagonistes du recepteur d'histamine h3 |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US8158673B2 (fr) |
| EP (1) | EP1951660B1 (fr) |
| JP (2) | JP4319245B2 (fr) |
| KR (1) | KR101025358B1 (fr) |
| CN (1) | CN101296898B (fr) |
| AP (1) | AP2403A (fr) |
| AR (1) | AR056879A1 (fr) |
| AU (1) | AU2006307645B2 (fr) |
| BR (1) | BRPI0617797A2 (fr) |
| CA (1) | CA2621323C (fr) |
| CR (1) | CR9910A (fr) |
| CU (1) | CU23806B7 (fr) |
| DK (1) | DK1951660T3 (fr) |
| DO (1) | DOP2006000239A (fr) |
| EA (1) | EA013602B1 (fr) |
| EC (1) | ECSP088373A (fr) |
| ES (1) | ES2444370T3 (fr) |
| GE (1) | GEP20104937B (fr) |
| GT (1) | GT200600471A (fr) |
| HN (1) | HN2006036385A (fr) |
| HR (1) | HRP20140061T1 (fr) |
| IL (1) | IL189866A (fr) |
| MA (1) | MA29888B1 (fr) |
| MY (1) | MY145001A (fr) |
| NI (1) | NI200800132A (fr) |
| NL (1) | NL1032713C2 (fr) |
| NO (1) | NO20082264L (fr) |
| NZ (1) | NZ566488A (fr) |
| PE (1) | PE20070720A1 (fr) |
| PL (1) | PL1951660T3 (fr) |
| PT (1) | PT1951660E (fr) |
| RS (2) | RS53153B (fr) |
| SI (1) | SI1951660T1 (fr) |
| TN (1) | TNSN08150A1 (fr) |
| TW (1) | TWI318206B (fr) |
| UA (1) | UA88719C2 (fr) |
| UY (1) | UY29882A1 (fr) |
| WO (1) | WO2007049123A1 (fr) |
| ZA (1) | ZA200803130B (fr) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158673B2 (en) * | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| EP2124933B1 (fr) * | 2007-01-22 | 2012-10-17 | Pfizer Products Inc. | Sel tosylate d'un composé thérapeutique et compositions thérapeutiques le contenant |
| WO2008108445A1 (fr) | 2007-03-07 | 2008-09-12 | Takeda Pharmaceutical Company Limited | Dérivés de benzodiazépine et utilisation de ces derniers |
| TWI432422B (zh) | 2007-08-22 | 2014-04-01 | Astrazeneca Ab | 環丙基醯胺衍生物 |
| AU2008332880C1 (en) * | 2007-12-07 | 2012-07-19 | Pfizer Inc. | Tosylate salt of trans-N-isobutyl-3-fluoro-3- [3-fluoro-4- (pyrrolidin-1-yl-methyl) -phenyl] cyclobut anecarboxamide |
| JP5780954B2 (ja) | 2008-05-08 | 2015-09-16 | エヴォテック・アクチエンゲゼルシャフト | ヒスタミンｈ３受容体アンタゴニストとしてのアゼチジン類及びシクロブタン類 |
| TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| AU2011218492B2 (en) | 2010-02-18 | 2014-11-13 | Astrazeneca Ab | New crystalline form of a cyclopropyl benzamide derivative |
| EP2691393B1 (fr) | 2011-03-31 | 2016-09-14 | Pfizer Inc | Nouvelles pyridones bicycliques |
| WO2012172449A1 (fr) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactames convenant comme inhibiteurs des bêta-sécrétases |
| WO2013030713A1 (fr) | 2011-08-31 | 2013-03-07 | Pfizer Inc. | Hexahydropyrano[3,4-d][1,3]thiazine-2-amines |
| WO2013151982A1 (fr) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Méthodes et composés utiles pour traiter le prurit, et procédés d'identification desdits composés |
| WO2013164730A1 (fr) | 2012-05-04 | 2013-11-07 | Pfizer Inc. | Composés d'hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par des hétérocycliques à titre d'inhibiteurs d'app, bace1 et bace2 |
| CN104395315B (zh) | 2012-06-29 | 2016-08-17 | 辉瑞大药厂 | 作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类 |
| US9260455B2 (en) | 2012-09-20 | 2016-02-16 | Pfizer Inc. | Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| WO2014091352A1 (fr) | 2012-12-11 | 2014-06-19 | Pfizer Inc. | Composés d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1 |
| JP6162820B2 (ja) | 2012-12-19 | 2017-07-12 | ファイザー・インク | 炭素環式および複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
| EP2956458B1 (fr) | 2013-02-13 | 2017-08-09 | Pfizer Inc | Composés hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par un hétéroaryle |
| US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| ES2638850T3 (es) | 2013-02-19 | 2017-10-24 | Pfizer Inc. | Compuestos de azabenzimidazol como inhibidores de las isoenzimas de la PDE4 para el tratamiento de trastornos del SNC y otros trastornos |
| JP6425717B2 (ja) | 2013-10-04 | 2018-11-21 | ファイザー・インク | ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン |
| ES2663622T3 (es) | 2013-12-17 | 2018-04-16 | Pfizer Inc. | Novedosas 1H-pirrolo[2,3-b]piridinas 3,4-disustituidas y 7H-pirrolo[2,3-c]piridacinas 4,5-disustituidas como inhibidores de LRRK2 |
| CR20160454A (es) | 2014-04-01 | 2016-12-06 | Pfizer | CROMENO Y 1,1 a,2,7b—TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS |
| MD20160105A2 (ro) | 2014-04-10 | 2017-03-31 | Pfizer Inc. | 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide |
| JP6713982B2 (ja) | 2014-07-24 | 2020-06-24 | ファイザー・インク | ピラゾロピリミジン化合物 |
| TN2017000031A1 (en) | 2014-08-06 | 2018-07-04 | Pfizer | Imidazopyridazine compounds |
| SG11201705780PA (en) | 2015-02-03 | 2017-08-30 | Pfizer | Novel cyclopropabenzofuranyl pyridopyrazinediones |
| KR20180004817A (ko) | 2015-06-17 | 2018-01-12 | 화이자 인코포레이티드 | 삼환형 화합물 및 포스포다이에스터라제 억제제로서 이의 용도 |
| MX377305B (es) | 2015-09-14 | 2025-03-07 | Pfizer | DERIVADOS DE IMIDAZO[4,5-c]QUINOLINA E IMIDAZO[4,5-c][1,5]NAFTIRIDINA NOVEDOSOS COMO INHIBIDORES DE LRRK2. |
| EP3353182A1 (fr) | 2015-09-24 | 2018-08-01 | Pfizer Inc | Dérivés de tétrahydropyrano[3,4-d][1,3]oxazine et leur utilisation en tant qu'inhibiteurs de bace |
| JP2018531923A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド |
| WO2017051294A1 (fr) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(3-amino-2,5-diméthyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides utiles comme inhibiteurs de bace |
| AU2017223132B2 (en) | 2016-02-23 | 2019-12-05 | Pfizer Inc. | 6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |
| CN109641898B (zh) | 2016-07-01 | 2022-04-08 | 辉瑞公司 | 用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物 |
| AU2018230109B2 (en) | 2017-03-10 | 2022-05-12 | Pfizer Inc. | Cyclic substituted imidazo[4,5-c]quinoline derivatives |
| KR102582626B1 (ko) | 2017-03-10 | 2023-09-22 | 화이자 인코포레이티드 | Lrrk2 억제제로서의 신규 이미다조[4,5-c]퀴놀린 유도체 |
| CN110997693A (zh) | 2017-06-07 | 2020-04-10 | 阿德克斯公司 | τ聚集抑制剂 |
| WO2018234953A1 (fr) | 2017-06-22 | 2018-12-27 | Pfizer Inc. | Dérivés de dihydro-pyrrolo-pyridine |
| WO2019036725A2 (fr) | 2017-08-18 | 2019-02-21 | Adrx, Inc. | Inhibiteurs peptidiques d'agrégation de tau |
| EP4219464A1 (fr) | 2018-03-23 | 2023-08-02 | Pfizer Inc. | Pipérazine azaspiro derivaves |
| EP4297868A4 (fr) | 2021-02-23 | 2025-01-08 | Hoth Therapeutics, Inc. | Utilisation d'aprépitant pour le traitement de la maladie d'alzheimer |
| CN116514645A (zh) * | 2023-04-08 | 2023-08-01 | 绍兴上虞华伦化工有限公司 | 二氟-4溴苯甲醛及其制备工艺 |
| WO2025145091A1 (fr) | 2023-12-29 | 2025-07-03 | Pfizer Inc. | Formes cristallines d'un modulateur muscarinique m4 du récepteur et méthodes de traitement de maladies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6559140B2 (en) * | 2000-03-09 | 2003-05-06 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
| WO2002076925A2 (fr) | 2001-03-23 | 2002-10-03 | Eli Lilly And Company | Composes d'aryl alkylamines non imidazole comme antagonistes des recepteurs h3 de l'histamine, preparation et applications therapeutiques |
| US7671047B2 (en) * | 2002-06-19 | 2010-03-02 | Sanofi-Aventis Deutschland Gmbh | Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| JP2004131497A (ja) * | 2002-09-18 | 2004-04-30 | Satoshi Shuto | シスシクロプロパン誘導体 |
| DE602004026068D1 (de) * | 2003-07-29 | 2010-04-29 | High Point Pharmaceuticals Llc | Pyridazinyl-piperazine und deren verwendung als histamin-h3-rezeptorliganden |
| CA2551037A1 (fr) * | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de piperidine |
| JP2007519707A (ja) | 2004-02-02 | 2007-07-19 | ファイザー・プロダクツ・インク | ヒスタミン−３受容体モジュレーター |
| ES2337376T3 (es) * | 2004-04-01 | 2010-04-23 | Eli Lilly And Company | Agentes receptores de la histamina h3, preparacion y usos terapeuticos. |
| US7456164B2 (en) * | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (fr) * | 2004-05-12 | 2005-11-16 | Pfizer Limited | Dérivés de tetrahydronaphthyridine en tant que ligands de récepteur H3 d'histamine |
| ES2354569T3 (es) | 2005-06-22 | 2011-03-16 | Pfizer Products Inc. | Antagonistas del receptor de histamina-3. |
| US8158673B2 (en) * | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| EP2124933B1 (fr) * | 2007-01-22 | 2012-10-17 | Pfizer Products Inc. | Sel tosylate d'un composé thérapeutique et compositions thérapeutiques le contenant |
-
2006
- 2006-10-13 US US11/549,175 patent/US8158673B2/en not_active Expired - Fee Related
- 2006-10-16 CN CN2006800399763A patent/CN101296898B/zh not_active Expired - Fee Related
- 2006-10-16 ES ES06809114.9T patent/ES2444370T3/es active Active
- 2006-10-16 UA UAA200802656A patent/UA88719C2/ru unknown
- 2006-10-16 PT PT68091149T patent/PT1951660E/pt unknown
- 2006-10-16 EA EA200800946A patent/EA013602B1/ru not_active IP Right Cessation
- 2006-10-16 WO PCT/IB2006/002977 patent/WO2007049123A1/fr not_active Ceased
- 2006-10-16 SI SI200631724T patent/SI1951660T1/sl unknown
- 2006-10-16 RS RS20140034A patent/RS53153B/sr unknown
- 2006-10-16 AP AP2008004401A patent/AP2403A/xx active
- 2006-10-16 KR KR1020087009991A patent/KR101025358B1/ko not_active Expired - Fee Related
- 2006-10-16 AU AU2006307645A patent/AU2006307645B2/en not_active Ceased
- 2006-10-16 GE GEAP200610660A patent/GEP20104937B/en unknown
- 2006-10-16 BR BRPI0617797-2A patent/BRPI0617797A2/pt not_active IP Right Cessation
- 2006-10-16 PL PL06809114T patent/PL1951660T3/pl unknown
- 2006-10-16 NZ NZ566488A patent/NZ566488A/en not_active IP Right Cessation
- 2006-10-16 CA CA2621323A patent/CA2621323C/fr not_active Expired - Fee Related
- 2006-10-16 RS RSP-2008/0173A patent/RS20080173A/sr unknown
- 2006-10-16 DK DK06809114.9T patent/DK1951660T3/da active
- 2006-10-16 JP JP2008537213A patent/JP4319245B2/ja not_active Expired - Fee Related
- 2006-10-16 HR HRP20140061TT patent/HRP20140061T1/hr unknown
- 2006-10-16 EP EP06809114.9A patent/EP1951660B1/fr active Active
- 2006-10-20 NL NL1032713A patent/NL1032713C2/nl not_active IP Right Cessation
- 2006-10-24 PE PE2006001288A patent/PE20070720A1/es not_active Application Discontinuation
- 2006-10-25 UY UY29882A patent/UY29882A1/es not_active Application Discontinuation
- 2006-10-25 AR ARP060104658A patent/AR056879A1/es active IP Right Grant
- 2006-10-25 GT GT200600471A patent/GT200600471A/es unknown
- 2006-10-26 HN HN2006036385A patent/HN2006036385A/es unknown
- 2006-10-26 DO DO2006000239A patent/DOP2006000239A/es unknown
- 2006-10-26 TW TW095139560A patent/TWI318206B/zh not_active IP Right Cessation
-
2008
- 2008-02-28 IL IL189866A patent/IL189866A/en not_active IP Right Cessation
- 2008-04-02 TN TNP2008000150A patent/TNSN08150A1/fr unknown
- 2008-04-09 ZA ZA200803130A patent/ZA200803130B/xx unknown
- 2008-04-15 EC EC2008008373A patent/ECSP088373A/es unknown
- 2008-04-23 CU CU20080069A patent/CU23806B7/es not_active IP Right Cessation
- 2008-04-23 CR CR9910A patent/CR9910A/es not_active Application Discontinuation
- 2008-04-24 MY MYPI20081265A patent/MY145001A/en unknown
- 2008-04-25 MA MA30879A patent/MA29888B1/fr unknown
- 2008-04-28 NI NI200800132A patent/NI200800132A/es unknown
- 2008-05-16 NO NO20082264A patent/NO20082264L/no not_active Application Discontinuation
-
2009
- 2009-03-10 JP JP2009055839A patent/JP5064427B2/ja not_active Expired - Fee Related
-
2012
- 2012-03-09 US US13/415,944 patent/US8389743B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN08150A1 (fr) | Antagonistes du recepteur d'histamine h3 | |
| WO2007088450A3 (fr) | Chromane antagoniste du récepteur h-3 | |
| WO2007105053A3 (fr) | Tétralines en tant qu'antagonistes du récepteur h-3 | |
| ATE488496T1 (de) | Histamin-3-rezeptorantagonisten | |
| WO2007063385A3 (fr) | Antagonistes des recepteurs de l'histamine 3 pour des amines spirocycliques | |
| WO2007138431A3 (fr) | Antagonistes de l'éther histamine-3 azabicyclique | |
| CN1214634A (zh) | 止痒药物 | |
| MX2009007782A (es) | Sal de tosilato de un compuesto terapeutico y composiciones farmaceuiticas de la misma. | |
| EA018064B1 (ru) | Способ лечения депрессии | |
| CN1261887A (zh) | 氮杂环丁基丙基哌啶衍生物、中间体以及作为速激肽拮抗剂的用途 | |
| BRPI0513486A (pt) | derivados de cicloamino 1,3 substituìdo e seu emprego como antagonistas de receptor de histamina-3 | |
| US20100048630A1 (en) | Methods for treating cns disorders | |
| MA35194B1 (fr) | Derives de benzamide substitues | |
| JP6175054B2 (ja) | ヒストンアセチルトランスフェラーゼ活性剤の使用 | |
| JP2007522095A (ja) | ジプラシドンを用いた不安の治療 | |
| US20230181572A1 (en) | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder | |
| CA3010727C (fr) | Agent de traitement prophylactique ou therapeutique du delire | |
| MX2007003587A (es) | Antagonistas de los receptores de histamina-3. | |
| CN113677345A (zh) | 用于治疗孤独症谱系障碍的氨基甲酰基环己烷衍生物 | |
| WO2006024955A8 (fr) | Antagonistes des recepteurs d'amine histamine-3 azabicycliques | |
| BRPI0512567A (pt) | compostos antagonistas de receptor de histamina-3 diazabicìclico e respectivas composições farmacêuticas | |
| WO2009128479A1 (fr) | Dérivé d'imidazoline | |
| KR100863384B1 (ko) | 아고멜라틴과 노르아드레날린 재흡수 억제제 사이의 신규한 회합 및 이를 포함하는 약제학적 조성물 | |
| CN120247837A (zh) | 一类新型苯甲酰胺衍生物、其制备方法及其作为药物的用途 | |
| TH88617A (th) | ฮิสทามีน-3 รีเซพเตอร์ แอนทาโกนิสท์ |